Assistant Professor, Medicine, University of Pittsburgh School of Medicine
Oncology
Dr. Ahmad Tarhini, MD
|
|
Give Review
Dr. Ahmad Tarhini is an expert in the field of Oncology. Ahmad Tarhini has written publications. He has 58 publications published with PubMed. The lastest paper is: 'Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon- but Not Observation in Intermediate Risk Melanoma Patients.' He accepts all Medicare patients.
Publications
- Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic Melanoma: a randomized clinical trial.
- Melanoma Adjuvant Therapy.
- Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk Melanoma treated with adjuvant interferon alfa.
- PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines.
- ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602).
- Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung Cancer.
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
- The accuracy of predicting survival in individual patients with Cancer.
- Tremelimumab: a review of development to date in solid Tumors.
- Comparative clinical benefits of Systemic adjuvant therapy for paradigm solid tumors.
- A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protec...
- Phase II study of everolimus (RAD001) in previously treated small cell lung Cancer.
- Releasing the brake on the immune System: ipilimumab in melanoma and other tumors.
- Prognostic significance of autoimmunity during treatment of Melanoma with interferon.
- CTLA-4-blocking immunotherapy with ipilimumab for advanced Melanoma.
- Cutaneous melanoma: a model to study Cancer metastasis.
- Neoadjuvant therapy for high-risk bulky regional Melanoma.
- Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin.
- Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma.
- Adjuvant therapy: Melanoma.
- [Clonal eosinophilia revealed by recurrent Staphylococcus aureus infection].
- Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced Melanoma and other solid tu...
- Assessing oncologic benefit in clinical trials of immunotherapy agents.
- Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.
- Advances in adjuvant therapy: potential for prognostic and predictive biomarkers.
- A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected Melanoma.
- Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management.
- Adjuvant immunotherapy of Melanoma and development of new approaches using the neoadjuvant approach.
- Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.
- Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy.
- Adjuvant high-dose interferon-alpha therapy for high-risk Melanoma.
- Management of Brain metastases in patients with melanoma.
- First International Symposium on Melanoma and Other Cutaneous Malignancies.
- The antihypertensive and vasodilator effects of aqueous extract from Berberis vulgaris fruit on hypertensive rats.
- Novel agents in development for the treatment of Melanoma.
- Does childhood vaccination and exposure to infection improve long-term survival in patients with malignant Melanoma?
- Interleukin-2 for the treatment of Melanoma.
- Cutaneous Melanoma: available therapy for metastatic disease.
- Response to "helping Melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b".
- Oblimersen in the treatment of metastatic Melanoma.
- Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic Melanoma who have experienced progression after biochemotherapy.
- Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of Cancer.
- Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III Melanoma.
- Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for Melanoma: expert opinion.
- Safety and efficacy of arsenic trioxide for patients with advanced metastatic Melanoma.
- Next generation of immunotherapy for Melanoma.
- A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic Melanoma.
- Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced Cancers.
- Prognostic significance of serum S100B protein in high-risk surgically resected Melanoma patients participating in Intergroup Trial ECOG 1694.
- Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic Leukemia.
- Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk Melanoma?
- A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic Melanoma.
- Biomarkers of therapeutic response in Melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
- Despite past disappointments, the future of Melanoma therapy appears bright.
- Clinical and immunologic basis of interferon therapy in Melanoma.
- Outcome predictors of Gamma Knife surgery for melanoma Brain metastases. Clinical article.
- CTLA-4 blockade: therapeutic potential in Cancer treatments.
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Coventry Health America PPO
- First Health (Coventry Health Care) PPO
- Community Blue PPO
- Choice Care PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- UPMC PPO
Education
-
University of Pittsburgh Medical Center
Hospital
-
UPMC Presbyterian Shadyside
Drug Facts
| NPI NUMBER | 1811934755 | |
| NPPES Provider LastName | TARHINI | |
| NPPES Provider FirstName | AHMAD | |
| NPPES Provider ZIPCode | 152132546 | |
| NPPES Provider State | PA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 134.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1811934755 |
| Last Name Of The Provider | TARHINI |
| First Name Of The Provider | AHMAD |
| View All |
Similar Doctors
|
|
Dr. John Lister, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Narinder K. Malhotra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jane M. Raymond, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roy E. Smith, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Entezam A. Sahovic, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Antonios Christou, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zella R. Zeigler, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Lanie K. Francis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald G. Stoller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saima Sharif, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sangeeta Goswami, MD |
|
|
Dr. Dhaval R. Mehta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Rajiv Jain, MB |
|
|
Zhineng J. Yang |